Influence of genetics and the pre-vaccination blood transcriptome on the variability of antibody levels after vaccination against Mycoplasma hyopneumoniae in pigs.
Journal
Genetics, selection, evolution : GSE
ISSN: 1297-9686
Titre abrégé: Genet Sel Evol
Pays: France
ID NLM: 9114088
Informations de publication
Date de publication:
18 Mar 2021
18 Mar 2021
Historique:
received:
06
08
2020
accepted:
16
02
2021
entrez:
18
3
2021
pubmed:
19
3
2021
medline:
20
7
2021
Statut:
epublish
Résumé
The impact of individual genetic and genomic variations on immune responses is an emerging lever investigated in vaccination strategies. In our study, we used genetic and pre-vaccination blood transcriptomic data to study vaccine effectiveness in pigs. A cohort of 182 Large White pigs was vaccinated against Mycoplasma hyopneumoniae (M. hyo) at weaning (28 days of age), with a booster 21 days later. Vaccine response was assessed by measuring seric M. hyo antibodies (Ab) at 0 (vaccination day), 21 (booster day), 28, 35, and 118 days post-vaccination (dpv). Inter-individual variability of M. hyo Ab levels was observed at all time points and the corresponding heritabilities ranged from 0.46 to 0.57. Ab persistence was higher in females than in males. Genome-wide association studies with a 658 K SNP panel revealed two genomic regions associated with variations of M. hyo Ab levels at 21 dpv at positions where immunity-related genes have been mapped, DAB2IP on chromosome 1, and ASAP1, CYRIB and GSDMC on chromosome 4. We studied covariations of Ab responses with the pre-vaccination blood transcriptome obtained by RNA-Seq for a subset of 82 pigs. Weighted gene correlation network and differential expression analyses between pigs that differed in Ab responses highlighted biological functions that were enriched in heme biosynthesis and platelet activation for low response at 21 dpv, innate antiviral immunity and dendritic cells for high response at 28 and 35 dpv, and cell adhesion and extracellular matrix for high response at 118 dpv. Sparse partial least squares discriminant analysis identified 101 genes that efficiently predicted divergent responders at all time points. We found weak negative correlations of M. hyo Ab levels with body weight traits, which revealed a trade-off that needs to be further explored. We confirmed the influence of the host genetics on vaccine effectiveness to M. hyo and provided evidence that the pre-vaccination blood transcriptome co-varies with the Ab response. Our results highlight that both genetic markers and blood biomarkers could be used as potential predictors of vaccine response levels and more studies are required to assess whether they can be exploited in breeding programs.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of individual genetic and genomic variations on immune responses is an emerging lever investigated in vaccination strategies. In our study, we used genetic and pre-vaccination blood transcriptomic data to study vaccine effectiveness in pigs.
RESULTS
RESULTS
A cohort of 182 Large White pigs was vaccinated against Mycoplasma hyopneumoniae (M. hyo) at weaning (28 days of age), with a booster 21 days later. Vaccine response was assessed by measuring seric M. hyo antibodies (Ab) at 0 (vaccination day), 21 (booster day), 28, 35, and 118 days post-vaccination (dpv). Inter-individual variability of M. hyo Ab levels was observed at all time points and the corresponding heritabilities ranged from 0.46 to 0.57. Ab persistence was higher in females than in males. Genome-wide association studies with a 658 K SNP panel revealed two genomic regions associated with variations of M. hyo Ab levels at 21 dpv at positions where immunity-related genes have been mapped, DAB2IP on chromosome 1, and ASAP1, CYRIB and GSDMC on chromosome 4. We studied covariations of Ab responses with the pre-vaccination blood transcriptome obtained by RNA-Seq for a subset of 82 pigs. Weighted gene correlation network and differential expression analyses between pigs that differed in Ab responses highlighted biological functions that were enriched in heme biosynthesis and platelet activation for low response at 21 dpv, innate antiviral immunity and dendritic cells for high response at 28 and 35 dpv, and cell adhesion and extracellular matrix for high response at 118 dpv. Sparse partial least squares discriminant analysis identified 101 genes that efficiently predicted divergent responders at all time points. We found weak negative correlations of M. hyo Ab levels with body weight traits, which revealed a trade-off that needs to be further explored.
CONCLUSIONS
CONCLUSIONS
We confirmed the influence of the host genetics on vaccine effectiveness to M. hyo and provided evidence that the pre-vaccination blood transcriptome co-varies with the Ab response. Our results highlight that both genetic markers and blood biomarkers could be used as potential predictors of vaccine response levels and more studies are required to assess whether they can be exploited in breeding programs.
Identifiants
pubmed: 33731010
doi: 10.1186/s12711-021-00614-5
pii: 10.1186/s12711-021-00614-5
pmc: PMC7972226
doi:
Substances chimiques
Antibodies
0
Heme
42VZT0U6YR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Subventions
Organisme : Horizon 2020
ID : Grant Agreement n°633184
Références
Lancet. 2002 Sep 28;360(9338):991-5
pubmed: 12383669
NPJ Vaccines. 2020 Jan 3;5(1):1
pubmed: 31908850
J Gastroenterol Hepatol. 2015 May;30(5):891-9
pubmed: 25389088
Vet J. 2011 Apr;188(1):48-52
pubmed: 20605734
J Natl Cancer Inst. 2007 Dec 19;99(24):1836-44
pubmed: 18073375
Vaccine. 2017 Mar 7;35(10):1390-1394
pubmed: 28189400
Mamm Genome. 2010 Aug;21(7-8):409-18
pubmed: 20567833
BMC Genomics. 2017 Dec 13;18(1):967
pubmed: 29237423
Nat Immunol. 2014 Feb;15(2):195-204
pubmed: 24336226
Int J Biol Sci. 2013 Sep 20;9(9):907-16
pubmed: 24155665
Am J Hum Genet. 2009 Jan;84(1):66-71
pubmed: 19110211
Res Vet Sci. 2001 Aug;71(1):1-7
pubmed: 11666141
Cell. 2014 Apr 10;157(2):499-513
pubmed: 24725414
Microorganisms. 2020 Jul 29;8(8):
pubmed: 32751315
Vaccine. 2012 Jul 6;30(32):4778-84
pubmed: 22658931
BMC Genomics. 2013 Dec 17;14:894
pubmed: 24341289
Vaccine. 2019 Mar 22;37(13):1743-1755
pubmed: 30808565
Virus Res. 2015 Dec 2;210:327-36
pubmed: 26362524
Vaccine. 1999 Mar 5;17(9-10):1024-34
pubmed: 10195611
PLoS One. 2012;7(3):e33526
pubmed: 22438944
PLoS Genet. 2012;8(3):e1002491
pubmed: 22423221
BMC Genet. 2013 May 10;14:42
pubmed: 23663563
BMC Bioinformatics. 2011 Jun 22;12:253
pubmed: 21693065
Vet Microbiol. 2007 May 16;122(1-2):97-107
pubmed: 17303351
Genes Immun. 2004 Mar;5(2):122-9
pubmed: 14737096
Methods Ecol Evol. 2016 Jul;7(7):792-799
pubmed: 27478587
Nat Immunol. 2009 Jan;10(1):116-125
pubmed: 19029902
Genome Med. 2018 Jul 27;10(1):59
pubmed: 30053915
Trans R Soc Trop Med Hyg. 2015 Jan;109(1):9-15
pubmed: 25573105
Cell Rep. 2019 Jun 11;27(11):3241-3253.e4
pubmed: 31189108
Hum Vaccin Immunother. 2016 Apr 2;12(4):907-15
pubmed: 26809773
Aust Vet J. 1997 Jul;75(7):504-11
pubmed: 9258425
Vaccine. 2001 Mar 21;19(17-19):2434-9
pubmed: 11257374
Immunology. 2019 Jan;156(1):33-46
pubmed: 30317555
Front Immunol. 2018 Jan 11;8:1962
pubmed: 29375578
Cell. 2016 Nov 17;167(5):1415-1429.e19
pubmed: 27863252
NPJ Vaccines. 2018 Oct 3;3:41
pubmed: 30302283
Jpn J Cancer Res. 2001 Feb;92(2):140-51
pubmed: 11223543
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Genome Res. 2013 Sep;23(9):1474-85
pubmed: 23800453
J Immunol. 1998 Jul 15;161(2):829-35
pubmed: 9670960
Nat Genet. 2015 May;47(5):523-527
pubmed: 25774636
PLoS One. 2011;6(7):e22717
pubmed: 21829490
Immunogenetics. 2014 Aug;66(7-8):493-9
pubmed: 24811271
Oncotarget. 2016 Jan 26;7(4):3766-76
pubmed: 26658103
Am J Vet Res. 1984 Jun;45(6):1216-8
pubmed: 6331234
J Infect Dis. 2018 Jan 30;217(4):560-566
pubmed: 29253144
Vaccine. 2006 Nov 30;24(49-50):7081-6
pubmed: 16934376
J Viral Hepat. 2019 Nov;26(11):1318-1329
pubmed: 31243853
Vaccine. 2013 Feb 18;31(9):1305-11
pubmed: 23306368
Front Immunol. 2019 May 24;10:1087
pubmed: 31178860
Acta Vet Hung. 2003;51(3):273-81
pubmed: 14516156
Transbound Emerg Dis. 2018 May;65 Suppl 1:110-124
pubmed: 28834294
Genes Immun. 2016 Dec;17(7):371-379
pubmed: 27534615
Genomics. 2007 May;89(5):618-29
pubmed: 17350798
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Vaccine. 2014 Mar 26;32(15):1661-9
pubmed: 24513009
Blood. 2011 May 19;117(20):5438-48
pubmed: 21444915
J Clin Invest. 2019 Mar 7;129(5):1960-1971
pubmed: 30843873
BMC Biol. 2010 Jul 01;8:84
pubmed: 20619006
Vaccine. 2012 Jun 13;30(28):4182-9
pubmed: 22542470
Hum Mol Genet. 2013 May 15;22(10):2119-27
pubmed: 23314186
J Infect Dis. 2015 Mar 15;211(6):898-905
pubmed: 25293367
Semin Immunol. 2013 Apr;25(2):89-103
pubmed: 23755893
Trends Mol Med. 2015 Dec;21(12):789-801
pubmed: 26602762
Sci Rep. 2020 Jul 14;10(1):11546
pubmed: 32665671
Hum Mol Genet. 2014 Apr 15;23(8):2210-9
pubmed: 24282030
Immunity. 2018 Jun 19;48(6):1144-1159.e5
pubmed: 29884460
BMC Genomics. 2017 Nov 13;18(1):865
pubmed: 29132293